The latest market report published by Credence Research, Inc. “Global Hospital Acquired Disease Testing Market: Growth, Future Prospects, and Competitive Analysis, 2016 – 2028. The global hospital acquired disease testing market is anticipated to grow at a substantial CAGR of 17.9% in the upcoming years. The global Fermentation Chemicals industry was estimated to be worth USD 9.9 billion in 2022 and was expected to be worth USD 31.3 billion by 2030.
Dominant segments of the market in 2022 included the consumables and reagents segment, the immunoassay category, and the drug-resistance testing market. The urinary tract segment also held a significant market share due to the high prevalence of pneumonia in hospitalized patients.
Geographically, North America dominated the market for hospital acquired infections, largely due to increasing emphasis on healthy lifestyles and disease prevention among consumers. The U.S. and China emerged as the key countries influencing the market’s development, driven by factors such as an aging population, technological advancements in diagnostic tools, and rising government initiatives.
Despite these challenges, the market is highly competitive with several regional and multinational players working towards expanding their presence. A notable move in the market was the acquisition of the CEERAM by bioMérieux in January 2015. Major market players include Abbott Laboratories, Ecolab, Johnson & Johnson, Merck Kgaa, Bayer Schering Pharma Llc, Becton Dickinson And Company, Pfizer Inc., Steris Plc, Hologic, Inc., and Danaher Corporation.
The Hospital Acquired Disease Testing market continues to evolve with rising cases of infections such as CLABSI and CRBSI. Increased adoption of sophisticated testing kits for effective diagnosis and the ongoing development of advanced infection detection technologies are set to further drive the market in the foreseeable future.
Hospital Acquired Disease Testing Market Key Growth Trends have been a topic of discussion in the healthcare industry for several years now. With increasing incidences of hospital-acquired infections, the demand for efficient and accurate testing methods has risen significantly. The key growth trends that have emerged in this market include the development of advanced diagnostic technologies such as PCR-based assays, next-generation sequencing (NGS), and immunoassays which are more sensitive and specific than conventional culture-based methods. Additionally, there is a growing focus on infection control measures aimed at reducing the spread of pathogens within hospitals through training programs for staff members on proper hygiene practices, antimicrobial stewardship initiatives, and environmental disinfection protocols.
Why to Buy This Report-
- The report provides a qualitative as well as quantitative analysis of the global Hospital Acquired Disease Testing Market by segments, current trends, drivers, restraints, opportunities, challenges, and market dynamics with the historical period from 2016-2020, the base year- 2021, and the projection period 2022-2028.
- The report includes information on the competitive landscape, such as how the market’s top competitors operate at the global, regional, and country levels.
- In-depth analysis of the global market segmentation on the Component and Deployment
- Major nations in each region with their import/export statistics
- The global Hospital Acquired Disease Testing Market report also includes the analysis of the market at a global, regional, and country-level along with key market trends, major players analysis, market growth strategies, and key application areas.
Browse Full Report: https://www.credenceresearch.com/report/hospital-acquired-disease-testing-market